Ariel S Wirchnianski, Elisabeth K Nyakatura, Andrew S Herbert, Ana I Kuehne, Shawn A Abbasi, Catalina Florez, Nadia Storm, Lindsay G A McKay, Leandrew Dailey, Erin Kuang, Dafna M Abelson, Anna Z Wec, Srinjoy Chakraborti, Frederick W Holtsberg, Sergey Shulenin, Zachary A Bornholdt, M Javad Aman, Anna N Honko, Anthony Griffiths, John M Dye, Kartik Chandran, Jonathan R Lai
Monoclonal antibodies (mAbs) are an important class of antiviral therapeutics. MAbs are highly selective, well tolerated, and have long in vivo half-life as well as the capacity to induce immune-mediated virus clearance. Their activities can be further enhanced by integration of their variable fragments (Fvs) into bispecific antibodies (bsAbs), affording simultaneous targeting of multiple epitopes to improve potency and breadth and/or to mitigate against viral escape by a single mutation. Here, we explore a bsAb strategy for generation of pan-ebolavirus and pan-filovirus immunotherapeutics...
April 11, 2024: PLoS Pathogens